- Full Year 2023 Medacta Group SA Earnings Call TranscriptMar 13, 2024$83.91Earnings
- Full Year 2023 Medacta Group SA Corporate Sales Call TranscriptFeb 02, 2024
- Half Year 2023 Medacta Group SA Earnings Call TranscriptSep 22, 2023$83.91Earnings
- Half Year 2023 Medacta Group SA Corporate Sales Call TranscriptJul 28, 2023
- Full Year 2022 Medacta Group SA Earnings Call TranscriptMar 17, 2023$83.91Earnings
- Q4 2022 Medacta Group SA Unaudited Top-Line Figures Call TranscriptFeb 03, 2023
- Half Year 2022 Medacta Group SA Earnings Call TranscriptSep 09, 2022$86.33Earnings
- Half Year 2022 Medacta Group SA Earnings Call TranscriptJul 29, 2022$86Earnings
- Full Year 2021 Medacta Group SA Earnings Call TranscriptMar 11, 2022$124Earnings
- Q4 2021 Medacta Group SA Corporate Sales Call TranscriptJan 20, 2022
- Half Year 2021 Medacta Group SA Earnings Call TranscriptSep 10, 2021$123.5Earnings
- Half Year 2021 Medacta Group SA Corporate Sales Call TranscriptJul 20, 2021
- Full Year 2020 Medacta Group SA Earnings Call TranscriptMar 31, 2021$114.6Earnings
- Full Year 2020 Medacta Group SA Corporate Sales Call TranscriptJan 21, 2021
- Half Year 2020 Medacta Group SA Earnings Call TranscriptSep 07, 2020Earnings
- Half Year 2020 Medacta Group SA Earnings Call TranscriptJul 22, 2020$65Earnings
- Full Year 2019 Medacta Group SA Earnings Call TranscriptApr 06, 2020Earnings
Half Year 2023 Medacta Group SA Corporate Sales Call Transcript
Good afternoon. This is the Chorus Call conference operator. Welcome, and thank you for joining the Medacta First Half 2023 Preliminary Unaudited Top Line Figures Conference Call. (Operator Instructions)
At this time, I would like to turn the conference over to Mr. Francesco Siccardi, CEO of Medacta. Please go ahead, sir.
Thank you very much, and welcome to our first half top line figure presentation. I'm here with Corrado Farsetta and Giorgio Botta, our IR. And I'm happy to go over the highlights of the first half.
We have seen a very strong growth in terms of revenue, more than 21% at constant currency, 20.8% reported. The geographic performance was very strong, both in APAC and U.S., with an even stronger performance in the EMEA segment.
All our business lines were contributing to this performance with really a stellar performance in Knee and Shoulder. We have seen an overall strong market demand sustained by the so-called backlog recovery associated with some of the COVID slowdown and
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)